N-Acetyl Selank Amidate

Neuropeptide

Also known as: Selank (parent compound), TP-7, Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH2 (claimed modified form)

Tier 2, Investigational, human data

Studied in registered human trials with published pharmacokinetic data, but not approved. Dosing outside a trial protocol has no established safety margin.

Half-life

Not established

No pharmacokinetic half-life confirmable for the acetyl-amidate variant. For parent Selank, a tritium-labeling biodegradation study (Zolotarev et al., Bioorg Khim 2006, PMID 16637290) tracked intranasal breakdown in plasma/brain and identified metabolites (TKPRP, TKP, RP, GP) but reports no numeric plasma half-life. Widely repeated vendor figures (e.g. 20-30 min) could not be verified and are NOT recorded.

Dosing

No established dose

No mcg dosing figure confirmable from an allowed-host source for either the variant or parent Selank; the Russian GAD trial (PMID 18454096) does not report per-dose amount in the accessible abstract.

Regulatory status

Neither the N-acetyl-amidate variant nor parent Selank is approved by FDA or EMA. Parent Selank is registered/used as a medicinal anxiolytic in Russia per the Russian literature; this is not Western approval and does not extend to the modified analog.

Evidence base

human clinical · confidence: low

NOTE: allowed-host data exists for PARENT Selank, not for the N-acetyl-amidate variant specifically. Human evidence for parent Selank is a single small comparator trial (n=62, selank vs. medazepam) from a Russian institute, Russian-language only, no independent Western replication; PK/biodegradation data is rat-only. The only PubChem hit resembling the acetylated form (CID 133082488, 'N-Acetyl selank', MW 793.9) is formula-consistent with N-terminal acetylation of a FREE-ACID C-terminus, NOT the amidated carboxamide implied by the name, so MW is left null to avoid conflating two distinct molecules. Parent Selank itself is CID 11765600 (MW 751.9).

Safety

No safety data exist for the N-acetyl-amidate variant specifically. Parent Selank human safety data is limited to one small Russian GAD trial (n=62), not a general/research-use population; no modern Western safety review or pharmacovigilance. Absence of reported harm is not evidence of safety at other doses, routes, populations, or for the chemically modified analog.

Sources